16,000 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Bought by Chase Investment Counsel Corp

Chase Investment Counsel Corp purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,000 shares of the medical equipment provider’s stock, valued at approximately $1,431,000.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new stake in Lantheus in the 3rd quarter worth $1,066,000. Massachusetts Financial Services Co. MA bought a new stake in Lantheus in the 3rd quarter worth $25,955,000. Van ECK Associates Corp grew its holdings in Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $93.82 on Friday. The stock has a market cap of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The firm’s 50-day simple moving average is $89.80 and its two-hundred day simple moving average is $96.75.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.